Drug intelligence / Profile preview

GORD132

Development stage: Unknown
Lead developer: Gordion Bioscience
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

GORD132 is a bispecific antibody (BiAb) developed by Gordion Bioscience, specifically engineered to target MET (Hepatocyte Growth Factor Receptor) for the treatment of MET-amplified tumors. Utilizing Gordion's platform that identifies compensatory resistance mechanisms through machine learning analysis of patient tumor data, GORD132 is designed to simultaneously inhibit MET signaling and a secondary, undisclosed pathway. This dual-targeting approach aims to enhance therapeutic efficacy and prevent the emergence of drug resistance typically associated with MET inhibition. The drug is currently in Phase 1 clinical development.

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on GORD132.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GORD132.

Explore the full profile